IR-Med Performance dei guadagni passati

Il passato criteri di controllo 0/6

IR-Med's earnings have been declining at an average annual rate of -30.4%, while the Medical Equipment industry saw earnings growing at 12.9% annually.

Informazioni chiave

-30.4%

Tasso di crescita degli utili

-21.0%

Tasso di crescita dell'EPS

Medical Equipment Crescita del settore	8.9%
Tasso di crescita dei ricavi	n/a
Rendimento del capitale proprio	-956.7%
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

Ripartizione dei ricavi e delle spese

Come IR-Med guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

OTCPK:IRME Ricavi, spese e utili (USD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	-3	2	1
31 Mar 24	-4	3	2
31 Dec 23	-5	3	2
30 Sep 23	-6	4	2
30 Jun 23	-5	3	2
31 Mar 23	-5	3	2
31 Dec 22	-5	3	2
30 Sep 22	-4	2	2
30 Jun 22	-4	2	2
31 Mar 22	-4	2	2
31 Dec 21	-4	2	1
30 Sep 21	-3	2	1
30 Jun 21	-2	2	1
31 Mar 21	-1	1	0
31 Dec 20	-1	0	0

Guadagni di qualità: IRME is currently unprofitable.

Margine di profitto in crescita: IRME is currently unprofitable.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: IRME is unprofitable, and losses have increased over the past 5 years at a rate of 30.4% per year.

Accelerare la crescita: Unable to compare IRME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: IRME is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).

Rendimento del capitale proprio

ROE elevato: IRME has a negative Return on Equity (-956.75%), as it is currently unprofitable.

IR-Med Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Recent updates

IR-Med Inc. Announces Chief Executive Officer Changes

IR-Med Inc. Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers

IR-Med Inc. has filed an IPO in the amount of $8 million.

IR-Med Inc. Appoints Avital Rosenberg as A Class I Director and Member of the Audit Committee

IR-Med Inc.’s PressureSafe Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel’s Hmo

IR-Med Inc.'S PressureSafe Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries

IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16

IR-Med Inc., Annual General Meeting, Nov 07, 2023

IR-MED Announces Executive Changes Effective as of October 15, 2023

Ir-Med to Conduct Usability Study with Methodist Healthcare of San Antonio for Its Pressuresafe Device Which Is Slated for U.S. Launch in H1 2024

IR-Med Inc. Appoints Richard Serbin, Esq. to Its Advisory Board

Ir-Med Inc. Announces Interim Results from A Clinical Study of Pressuresafe

IR-Med Inc. Appoints Lynn Eschenbacher to its Advisory Board

IR-Med Inc., Annual General Meeting, Dec 12, 2022

IR-Med Announces Appointment of Moshe Gerber as Chief Executive Officer

International Display Advertising, Inc. (OTCPK:IDAD.D) completed the acquisition of IR Med, Ltd.

International Display Advertising, Inc. announced that it expects to receive $5 million in funding

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate